Side-Effect Management Archives - Page 39 of 40 - Cancer Therapy Advisor

Side-Effect Management

Oral Ruxolitinib Reduces Splenomegaly, Disease-Related Symptoms of Myelofibrosis vs. Best Available Therapy

In patients with myelofibrosis, continuous treatment with oral ruxolitinib vs. best available therapy resulted in marked and durable reductions in splenomegaly and disease-related symptoms as well as improvements in role functioning and quality of life (QOL), one of two Phase 3 studies published in the March 1, 2012, issue of the New England Journal of Medicine has found.

Annual BMD, Selective Oral Bisphosphonate Use Cost-Effective for Fracture Prevention in Postmenopausal Women Receiving AIs for Hormone-Positive Early Breast Cancer

Baseline and annual bone mineral density (BMD) screening with subsequent selective treatment with oral bisphosphonates where indicated in postmenopausal women receiving adjuvant aromatase inhibitors (AIs) for hormone-receptor early breast cancer is a cost-effective use of societal resources

Cervical Pulsed Radiofrequency Reduces Severe Chronic Pain, Opioid Use and Increases Quality of Life in Patients with Metastatic Breast Cancer

Cervical pulsed radiofrequency (PRF) can be used as a palliative option for the treatment of severe chronic pain in patients with malignant breast cancer when conventional pain management does not provide adequate pain control, according to a presentation at the American Academy of Pain Medicine 28th Annual Meeting.

Next post in Side Effect Management